Safety analysis of acyclovir use in neonates based on the FDA Adverse Event Reporting System Authors: Longbing He, Bo Wang, Yang Wang, Youshuai Chen Published: 2026 ABSTRACT Acyclovir is the first-line treatment for neonatal herpes simplex virus infection; however, safety evidence in neonates remains limited. This study aimed to evaluate the safety profile of acyclovir in neonates using real-world pharmacovigilance data from the Food and Drug Administration Adverse Event Reporting System. This retrospective observational study analyzed adverse event (AE) reports in neonates (≤28 days) in which acyclovir was identified as the primary suspected drug in the Food and Drug Administration Adverse Event Reporting System from 2004 to Q3 2024. Disproportionality analyses were performed using the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network, and empirical Bayesian geometric mean (EBGM). Positive risk signals were defined as those meeting the statistical significance criteria across all 4 methods. A total of 130 reports comprising 409 AEs were identified. Four system organ classes showed positive risk signals: skin and subcutaneous tissue disorders (ROR = 6.22, PRR = 5.88, lower limit of 95% confidence interval [CI] of the information component [IC025] = 1.98, lower limit of 95% CI of EBGM [EBGM05] = 4.16), general disorders and administration site conditions (ROR = 4.27, PRR = 3.47, IC025 = 1.47, EBGM05 = 2.85), hepatobiliary disorders (ROR = 3.85, PRR = 3.74, IC025 = 1.19, EBGM05 = 2.43), and renal and urinary disorders (ROR = 3.84, PRR = 3.70, IC025 = 1.24, EBGM05 = 2.51). At the preferred term level, 12 positive signals were detected, with the strongest signals observed for infusion site necrosis/edema (ROR = 939.92, 95% CI: 97.56–9055.25), arthritis (ROR = 179.47, 95% CI: 52.33–615.44), skin exfoliation/necrosis (ROR = 131.18, 95% CI: 46.00–374.06), and Kawasaki disease (ROR = 114.20, 95% CI: 36.21–360.15). Notably, Kawasaki disease, rectal hemorrhage, and necrotizing colitis were not described in existing product labeling. Acyclovir use in neonates may be associated with immune, gastrointestinal, hepatic, and renal AEs, underscoring the need for careful clinical monitoring. Further prospective studies are warranted to validate these associations. 1. Introduction Acyclovir, a synthetic purine nucleoside analog, plays an important role in the treatment of herpesvirus infections because of its distinct antiviral mechanism.[1–3] It is currently the preferred therapeutic agent for neonatal herpes simplex virus (HSV) infection.[4] Although neonatal HSV infection is relatively rare, it can cause severe complications and may be life-threatening.[5–7] The high-dose acyclovir regimen recommended by the American Academy of Pediatrics, 60 mg/kg/day, has been widely adopted worldwide for the management of neonatal HSV infection.[8,9] However, the US Food and Drug Administration (FDA) initially delayed formal approval of this high-dose regimen because of toxicity concerns, reflecting regulatory caution regarding the safety of acyclovir use in neonates.[10] Given the distinct physiological characteristics of neonates, including immature drug metabolism and excretory capacity, drug safety assessment is particularly important in this population. Although acyclovir use in adults and children has been relatively well studied, and potential adverse events (AEs) such as nephrotoxicity, neutropenia, and neurotoxicity have been documented, safety evidence regarding its use in neonates remains limited.[10–13] To the best of our knowledge, comprehensive evaluations of the safety profile of acyclovir in neonates remain scarce, which may complicate clinical decision-making. The FDA Adverse Event Reporting System (FAERS), a comprehensive database that collects postmarketing AE information on drugs and therapeutic biological products, provides a valuable platform for investigating drug-related AEs.[14,15] This study aimed to conduct an in-depth analysis of AE reports associated with neonatal acyclovir use in FAERS to characterize the safety profile of acyclovir in neonates and provide evidence to support clinical decision-making. 2. Methods 2.1. Study design and data source This study analyzed AE reports in neonates in which acyclovir was identified as the primary suspected drug. Neonates were defined as infants aged ≤28 days.[16] No restrictions were applied regarding sex or nationality. Data were obtained from the FAERS database, which has collected spontaneous AE reports worldwide since its establishment in 2004. The database contains patient demographic information, including age and weight, as well as drug information, AE records, and clinical outcome data. In this study, relevant AE reports from FAERS between 2004 and the third quarter of 2024 were retrieved for signal detection. Because this study was based exclusively on publicly available and deidentified FAERS data and involved no direct patient interaction or access to identifiable personal information, ethics approval and informed consent were not required in accordance with local regulations and institutional requirements. This study was reported in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology statement. 2.2. Data processing In accordance with the FDA-recommended data processing guidelines, duplicate AE reports were excluded as the initial step. For records with the same case ID, only the most recent report, determined by the report date, was retained. Because FAERS includes reports from diverse global sources, variations in drug-name representation were observed. Therefore, the MedEx-UIMA_1.8.3 system, developed by Vanderbilt University in the United States, was used to standardize drug names. Specifically, MedEx-UIMA_1.8.3 was applied to automatically extract and normalize drug names from FAERS reports.[17] This natural language processing system, which is based on the Unstructured Information Management Architecture framework, was used to identify mentions of acyclovir and its synonyms across drug-name fields, including generic names, brand names, and spelling variants. The search strategy included reports containing either “acyclovir” or its common brand name “Zovirax.” All identified variants were mapped to the standardized drug name “acyclovir,” enabling accurate retrieval and aggregation of relevant AE reports for subsequent disproportionality analyses. All AE names included in this study were coded according to preferred terms (PTs) in the Medical Dictionary for Regulatory Activities (MedDRA) and classified by system organ class (SOC). MedDRA is a standardized medical terminology developed by the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use to facilitate consistent and accurate international communication of medical information.[17] In FAERS, the reporter category indicates the source or submitter of an AE report and does not necessarily identify the clinician who established the diagnosis. Reports submitted by consumers or caregivers may be based on diagnoses, laboratory findings, discharge summaries, or other medical information provided by healthcare professionals. In this study, reported AEs were standardized using MedDRA PTs and subsequently grouped into SOCs for signal detection. Therefore, SOC categories should be interpreted as standardized pharmacovigilance classifications rather than diagnoses independently made by individual reporters. 2.3. AE signal detection AE signal detection aims to determine whether a specific AE is reported more frequently with the target drug than expected, thereby identifying a statistical association between the drug and the AE.[18] Commonly used disproportionality methods for AE signal detection include the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network, and empirical Bayesian geometric mean (EBGM).[19,20] The basic principles of these methods are presented in Table S1, Supplemental Digital Content 1, and their formulas and signal thresholds are listed in Table S2, Supplemental Digital Content 2. Because each detection method has specific strengths and limitations,[18–20] this study used a combined criterion to reduce potential bias associated with any single method. Specifically, an AE was considered to have a positive risk signal only when all 4 detection methods indicated a positive signal, suggesting a statistical association between acyclovir and the AE. 2.4. Statistical analysis Descriptive statistics were used to summarize the clinical characteristics of the neonates included in the database. Normally distributed continuous variables are presented as the mean ± standard deviation, whereas skewed continuous variables are presented as the median and interquartile range. Categorical variables are presented as frequencies and percentages. All acyclovir-related data were processed using R version 4.3.2 (R Foundation for Statistical Computing, Vienna, Austria).[21] 3. Results 3.1. General characteristics During the study period, 130 reports identified acyclovir as the primary suspected drug for AEs, comprising 409 documented AEs. The process of data screening and signal identification is shown in Figure 1. Flowchart of data screening and signal detection for acyclovir-related adverse events. BCPNN = Bayesian confidence propagation neural network, DEMO = demographic and administrative information, DRUG = drug/biological information, EBGM = empirical Bayesian geometric mean, PRR = proportional reporting ratio, PT = preferred term, REAC = adverse event coding, ROR = reporting odds ratio. The number of AE reports associated with neonatal acyclovir use increased over time, with reports from the most recent 6 years accounting for 49.23% of the total. Among these reports, male neonates accounted for a slightly higher proportion than female neonates: 46.92% versus 44.62%. The median age at acyclovir use was approximately 7 days, and the median body weight was 3.3 kg. Clinicians were the most common reporters of AEs, accounting for 46.92% of reports. Regarding clinical outcomes, apart from reports with unspecified serious outcomes, which accounted for 47.28%, the 3 most frequent outcomes were hospitalization or prolonged hospitalization (29.89%), life-threatening events (8.70%), and death (8.15%). These characteristics are summarized in detail in Table 1. Table 1General characteristics of adverse event reports of acyclovir from the FAERS database.CharacteristicsNumber of events (%)Year 2004–200813 (10.00) 2009–201322 (16.92) 2014–201831 (23.85) 2019–202352 (40.00) 202412 (9.23)Sex Female58 (44.62) Male61 (46.92) Unknown/unreported11 (8.46)Age (d)7.30 (0.00, 11.00)Weight (kg)3.30 (2.63, 3.70)Reporter Physician61 (46.92) Pharmacist24 (18.46) Consumer22 (16.92) Other health professional21 (16.15) Registered nurse1 (0.77) Unknown/unreported1 (0.77)Route Intravenous45 (34.62) Oral12 (9.23) Other/unreported73 (56.15)Outcomes Other serious87 (47.28) Hospitalization55 (29.89) Life-threatening16 (8.70) Death15 (8.15) Disability10 (5.43) Required intervention to prevent permanent impairment/damage1 (0.54)Reporter refers to the category of the individual submitting or transmitting the FAERS report and does not necessarily indicate the person who made the clinical diagnosis.FAERS = FDA Adverse Event Reporting System, FDA = Food and Drug Administration. General characteristics of adverse event reports of acyclovir from the FAERS database. Reporter refers to the category of the individual submitting or transmitting the FAERS report and does not necessarily indicate the person who made the clinical diagnosis. FAERS = FDA Adverse Event Reporting System, FDA = Food and Drug Administration. 3.2. Signal detection of AEs at the SOC level Among AE reports in which acyclovir was identified as the primary suspected drug, 18 SOCs were identified, of which 4 showed positive risk signals. The 4 SOCs and their corresponding signal strengths were as follows: Skin and subcutaneous tissue disorders: ROR = 6.22, PRR = 5.88, lower limit of 95% confidence interval [CI] of the information component (IC025) = 1.98, lower limit of 95% CI of EBGM (EBGM05) = 4.16. Skin and subcutaneous tissue disorders: ROR = 6.22, PRR = 5.88, lower limit of 95% confidence interval [CI] of the information component (IC025) = 1.98, lower limit of 95% CI of EBGM (EBGM05) = 4.16. General disorders and administration site conditions: ROR = 4.27, PRR = 3.47, IC025 = 1.47, EBGM05 = 2.85. General disorders and administration site conditions: ROR = 4.27, PRR = 3.47, IC025 = 1.47, EBGM05 = 2.85. Hepatobiliary disorders: ROR = 3.85, PRR = 3.74, IC025 = 1.19, EBGM05 = 2.43. Hepatobiliary disorders: ROR = 3.85, PRR = 3.74, IC025 = 1.19, EBGM05 = 2.43. Renal and urinary disorders: ROR = 3.84, PRR = 3.70, IC025 = 1.24, EBGM05 = 2.51. Renal and urinary disorders: ROR = 3.84, PRR = 3.70, IC025 = 1.24, EBGM05 = 2.51. The signal strengths for each SOC are summarized in Table 2. Table 2Signal strength of adverse events of acyclovir at the SOC level.SOCCase reportsROR (95% CI)PRR (95% CI)χ2IC (IC025)EBGM (EBGM05)Skin and subcutaneous tissue disorders276.22 (4.2–9.22)5.88 (4.05–8.53) 108.47 2.53 (1.98)5.79 (4.16)General disorders and administration site conditions1004.27 (3.4–5.35)3.47 (2.91–4.14) 186.98 1.78 (1.47)3.44 (2.85)Hepatobiliary disorders163.85 (2.33–6.37)3.74 (2.29–6.1) 32.06 1.89 (1.19)3.71 (2.43)Renal and urinary disorders203.84 (2.44–6.03)3.7 (2.4–5.69) 39.43 1.87 (1.24)3.67 (2.51)Gastrointestinal disorders291.92 (1.32–2.8)1.86 (1.31–2.65) 11.82 0.89 (0.35)1.85 (1.35)Vascular disorders101.57 (0.84–2.94)1.55 (0.84–2.85)1.990.63 (−0.23)1.55 (0.92)Investigations241.14 (0.76–1.73)1.14 (0.77–1.69)0.410.18 (−0.4)1.14 (0.8)Blood and lymphatic system disorders81.1 (0.55–2.22)1.1 (0.55–2.18)0.070.13 (−0.82)1.1 (0.61)Infections and infestations191.03 (0.65–1.64)1.03 (0.67–1.59)0.020.05 (−0.6)1.03 (0.7)Injury, poisoning, and procedural complications570.82 (0.62–1.09)0.85 (0.67–1.08)1.92−0.24 (−0.64)0.85 (0.67)Nervous system disorders150.61 (0.36–1.02)0.62 (0.38–1.01)3.62−0.68 (−1.4)0.62 (0.41)Cardiac disorders100.6 (0.32–1.13)0.61 (0.33–1.12)2.55−0.71 (−1.57)0.61 (0.36)Metabolism and nutrition disorders70.59 (0.28–1.24)0.59 (0.28–1.24)2−0.75 (−1.76)0.59 (0.32)Musculoskeletal and connective tissue disorders40.47 (0.18–1.27)0.48 (0.18–1.28)2.32−1.06 (−2.34)0.48 (0.21)Respiratory, thoracic, and mediastinal disorders160.44 (0.27–0.73)0.46 (0.28–0.75) 10.81 −1.11 (−1.81)0.46 (0.31)Psychiatric disorders40.44 (0.16–1.17)0.44 (0.17–1.17)2.89−1.18 (−2.45)0.44 (0.19)Pregnancy, puerperium, and perinatal conditions170.32 (0.2–0.52)0.35 (0.22–0.56) 23.61 −1.52 (−2.2)0.35 (0.23)Congenital, familial, and genetic disorders210.27 (0.17–0.42)0.31 (0.21–0.47) 39.26 −1.7 (−2.32)0.31 (0.21)Bolded values indicate a positive result. SOCs are MedDRA-based classification categories derived from reported preferred terms and should not be interpreted as independent diagnoses made by all reporter types.95% CI = 95% confidence interval, χ2 = chi-squared, EBGM = empirical Bayesian geometric mean, EBGM05 = lower limit of 95% CI of EBGM, IC = information component, IC025 = lower limit of 95% CI of the IC, MedDRA = Medical Dictionary for Regulatory Activities, PRR = proportional reporting ratio, ROR = reporting odds ratio, SOC = system organ class. Signal strength of adverse events of acyclovir at the SOC level. Bolded values indicate a positive result. SOCs are MedDRA-based classification categories derived from reported preferred terms and should not be interpreted as independent diagnoses made by all reporter types. 95% CI = 95% confidence interval, χ2 = chi-squared, EBGM = empirical Bayesian geometric mean, EBGM05 = lower limit of 95% CI of EBGM, IC = information component, IC025 = lower limit of 95% CI of the IC, MedDRA = Medical Dictionary for Regulatory Activities, PRR = proportional reporting ratio, ROR = reporting odds ratio, SOC = system organ class. 3.3. Signal detection of AEs at the PT level At the PT level, this study identified positive risk signals with at least 3 reports. A total of 12 PTs met this criterion: infusion site necrosis/edema, arthritis, skin exfoliation/necrosis, Kawasaki disease, rectal hemorrhage, sinus tachycardia, thrombocytosis, acute kidney injury, hepatic failure, hyperbilirubinemia, necrotizing colitis, and renal failure. Detailed results are presented in Table 3. The 12 positive PT-level signals are further visualized in a forest plot showing RORs and corresponding 95% CIs (Fig. 2). Table 3Positive risk signal results for adverse events of acyclovir at the PT level.SOCPTsROR (95% CI)PRR (95% CI)χ2IC (IC025)EBGM (EBGM05)General disorders and administration site conditionsInfusion site necrosis/edema939.92 (97.56–9055.25)933.03 (97.95–8887.82)698.297.87 (5.97)234.01 (35.16)Musculoskeletal and connective tissue disordersArthritis179.47 (52.33–615.44)177.72 (52.72–599.09)447.346.83 (5.31)113.46 (40.46)Skin and subcutaneous tissue disordersSkin exfoliation/necrosis131.18 (46–374.06)129.59 (45.86–366.2)450.46.52 (5.18)91.77 (38.19)Vascular disordersKawasaki disease114.2 (36.21–360.15)113.09 (36.28–352.48)325.946.38 (4.92)83.2 (31.83)Gastrointestinal disordersRectal hemorrhage40.86 (12.22–136.62)40.57 (12.27–134.11)102.445.17 (3.65)36 (13.11)Cardiac disordersSinus tachycardia30.31 (9.23–99.55)30.1 (9.29–97.57)76.974.78 (3.28)27.53 (10.18)Blood and lymphatic system disordersThrombocytosis24.62 (8.86–68.45)24.39 (8.8–67.58)83.254.5 (3.18)22.69 (9.65)Renal and urinary disordersAcute kidney injury22.13 (10.22–47.92)21.77 (10.14–46.76)129.754.35 (3.31)20.41 (10.69)Hepatobiliary disordersHepatic failure19.17 (5.95–61.77)19.04 (5.99–60.52)48.344.17 (2.7)18 (6.76)Hepatobiliary disordersHyperbilirubinemia11.9 (5.23–27.04)11.74 (5.26–26.22)56.863.5 (2.4)11.35 (5.71)Gastrointestinal disordersNecrotizing colitis7.99 (2.95–21.66)7.92 (2.97–21.1)23.632.95 (1.66)7.75 (3.37)Renal and urinary disordersRenal failure6.06 (2.24–16.38)6.01 (2.26–16.01)16.422.56 (1.28)5.91 (2.57)No fewer than 3 cases were reported for a single PT.95% CI = 95% confidence interval, χ2 = chi-squared, EBGM = empirical Bayesian geometric mean, EBGM05 = lower limit of 95% CI of EBGM, IC = information component, IC025 = lower limit of 95% CI of the IC, PRR = proportional reporting ratio, PT = preferred term, ROR = reporting odds ratio, SOC = system organ class. Positive risk signal results for adverse events of acyclovir at the PT level. No fewer than 3 cases were reported for a single PT. 95% CI = 95% confidence interval, χ2 = chi-squared, EBGM = empirical Bayesian geometric mean, EBGM05 = lower limit of 95% CI of EBGM, IC = information component, IC025 = lower limit of 95% CI of the IC, PRR = proportional reporting ratio, PT = preferred term, ROR = reporting odds ratio, SOC = system organ class. Forest plot of positive risk signals for acyclovir-related adverse events at the preferred term level. The reporting odds ratio and corresponding 95% confidence interval (CI) are shown for each preferred term. Because of the wide range of signal strengths, the x-axis is displayed on a logarithmic scale. 4. Discussion This study, based on the FAERS database, systematically evaluated the safety profile of acyclovir use in neonates. Four SOCs and 12 PTs exhibiting positive risk signals were identified. Notably, several AEs, including Kawasaki disease, rectal hemorrhage, and necrotizing colitis, were not described in the current product labeling of acyclovir. These newly identified potential safety signals highlight the need for further investigation into the safety of acyclovir in neonates, particularly considering the unique physiological characteristics that may influence drug metabolism and adverse reactions in this population. By leveraging real-world pharmacovigilance data, this study provides a comprehensive assessment of acyclovir-associated AEs in neonates and offers evidence to support clinical decision-making regarding neonatal HSV treatment. These findings also provide a foundation for future studies investigating the safety mechanisms and optimal use of acyclovir in neonates. A potential association between Kawasaki disease and acyclovir use in neonates was identified in this study. To the best of our knowledge, this association has not been previously reported. Although the pathophysiological mechanisms of Kawasaki disease remain incompletely understood, current evidence suggests that abnormal immune activation may play an important role.[22,23] As an antiviral agent, acyclovir may be linked to Kawasaki disease through several possible mechanisms. First, certain drugs may induce systemic vasculitis,[24] which may share certain features with the vascular inflammation observed in Kawasaki disease. Second, valacyclovir, an acyclovir prodrug, has demonstrated immunomodulatory effects on activated macrophages in vitro, suggesting that acyclovir-related compounds may influence inflammatory signaling.[25] Third, a general mechanism proposed for idiosyncratic drug reactions is that reactive metabolites may bind to host proteins and render them immunogenic, potentially initiating immune-mediated injury.[26] However, whether this mechanism applies to acyclovir remains unknown. Importantly, the positive signal observed in this study indicates only a statistical association between acyclovir and Kawasaki disease and does not establish a causal relationship. Rectal hemorrhage was another AE with a strong signal in this study, although it has not been previously described in acyclovir product labeling. Several potential mechanisms may be considered. First, acyclovir exerts its antiviral effect primarily through the selective inhibition of viral DNA polymerase and shows substantially greater activity in virus-infected cells than in uninfected host cells. In patients with renal impairment, reduced renal clearance may lead to acyclovir accumulation. In addition, inhibition of mammalian cell growth has been observed at very high acyclovir concentrations (>300 μM).[27] Acute colitis following oral acyclovir administration has also been reported in 3 patients, including 1 patient who experienced recurrent colitic symptoms after rechallenge. A direct irritant effect of acyclovir on the large-bowel mucosa has therefore been proposed.[28] These observations raise the possibility that excessive acyclovir exposure or individual mucosal susceptibility could contribute to colonic mucosal injury and bleeding. Second, acyclovir-induced immune thrombocytopenia has been reported and may theoretically increase susceptibility to bleeding.[29] However, the available evidence remains limited, and neither of these proposed mechanisms has been established, particularly in neonates. Further clinical and experimental studies are therefore required to clarify the biological basis of the rectal hemorrhage signal identified in this study. Necrotizing colitis is a severe gastrointestinal disorder that primarily affects neonates and is characterized by intestinal inflammation and tissue necrosis.[30] Although its exact etiology remains incompletely understood, its pathogenesis is thought to be closely associated with impaired intestinal barrier function, bacterial translocation, and excessive inflammatory responses.[30,31] Montjaux-Régis et al reported a case of early necrotizing colitis in a full-term neonate receiving prophylactic acyclovir.[32] Although this case report provides preliminary evidence of a possible association between acyclovir and necrotizing colitis, available evidence remains limited, and further clinical and experimental studies are needed to clarify the underlying mechanisms and potential causal relationship. In clinical practice, the benefits and potential risks of acyclovir therapy should be carefully weighed, particularly in neonates at high risk for necrotizing colitis. Other AEs identified in this study were relatively common and showed both similarities to and differences from those reported in broader populations. Regarding cutaneous events, infusion site necrosis/edema showed the strongest signal in neonates. The predominance of infusion-site events may reflect local administration-site factors, although the underlying mechanism remains uncertain. In contrast, systemic severe cutaneous reactions, such as Stevens-Johnson syndrome, have been reported in broader populations receiving acyclovir.[12] Regarding hepatotoxicity, hyperbilirubinemia was a notable event in the neonatal reports analyzed in this study, whereas hepatic enzyme abnormalities have been described as the main hepatic adverse effects in broader populations.[33] Regarding nephrotoxicity, previous pharmacovigilance analyses have identified associations of acyclovir with acute kidney injury and renal impairment in a broader population composed predominantly of adults.[33] Consistent with these findings, our neonatal analysis identified positive signals for both acute kidney injury and renal failure. Acyclovir has low urinary solubility and may precipitate within the renal tubules, causing obstruction and crystal nephropathy.[34] However, neonates may be particularly susceptible to renal injury. One developmental factor that may contribute to this susceptibility is immature renal secretory function, as the reported maximum tubular secretion capacity in neonates is approximately 20% to 30% of that in adults.[35] Developmental differences in plasma protein binding may also alter the unbound drug fraction and drug disposition in neonates, although their specific contribution to acyclovir-associated nephrotoxicity remains uncertain.[35] These findings suggest that when acyclovir is used in neonates, clinicians should optimize infusion protocols and closely monitor renal function to improve drug safety in this vulnerable population. 4.1. Limitations This study has several limitations. First, because FAERS is a spontaneous reporting database, the results may be affected by underreporting; reporting bias, including preferential reporting of severe events or specific symptoms; and unmeasured confounding factors, including concomitant medications and underlying diseases. Second, FAERS does not consistently provide detailed information on drug dosage, treatment duration, or other clinical details, which limited further subgroup and sensitivity analyses. Third, signal detection can only indicate a statistical association; it cannot establish causality or estimate the incidence of AEs. Fourth, regarding the source of reported information, the reporter category in FAERS does not necessarily identify the healthcare professional who made the medical diagnosis. For reports submitted by consumers or caregivers, AE information may have been derived from medical records, laboratory findings, discharge summaries, or diagnoses communicated by clinicians; however, the diagnostic certainty and completeness of such information cannot be independently verified. Therefore, potential misclassification and incomplete reporting should be considered when interpreting SOC- and PT-level signals. Finally, although the number of AE reports associated with neonatal acyclovir use increased over time, the overall number of reports remained relatively limited. Therefore, future prospective, large-scale clinical and experimental studies are needed to clarify the safety profile and potential mechanisms of acyclovir in neonates. 5. Conclusion This real-world pharmacovigilance study identified potential safety signals associated with acyclovir use in neonates, particularly previously underrecognized AEs involving the immune and gastrointestinal systems. These findings help address existing gaps in neonatal drug safety evidence and provide clinically relevant information to support risk monitoring and regulatory decision-making. Further research is needed to elucidate the underlying mechanisms, optimize neonatal antiviral treatment strategies, and improve the safety of acyclovir use in neonates.